How Europe could have more Biotech Champions like argenx
For decades, the narrative of European biotech has been one of “innovation flight”: brilliant science...
Why the antimicrobial resistance crisis is bigger than cancer and how Immunethep is thinking differently
We’ve been hearing about the Antimicrobial Resistance (AMR) crisis for over a decade. Yet, according...
Biopharma family succession: Bial CEO António Portela’s strategy
In the high-stakes world of pharmaceutical innovation, few stories are as compelling as those of...
How AI, AlphaFold and Digital Twins are Transforming Biosolutions
Artificial intelligence is no longer a buzzword in biotech, it’s becoming core infrastructure. From protein...
How Camurus Is Transforming Generic Drugs Into Long-Acting Breakthroughs: Fredrik Tiberg on Innovation in Opioid Use Disorder Treatment
Turning Generics Into Game-Changing Therapies: Fredrik Tiberg of Camurus Explains the Power of Long-Acting Medicines...
Personalized Cancer Vaccines and Oncolytic Viruses: The Next Generation of Cancer Immunotherapy
For decades, cancer vaccines have promised much and delivered little. Early “off-the-shelf” approaches struggled to...
From Breakthrough to Maturity: How Cell Therapy Is Evolving
Cell therapy has come a long way in just over a decade. What began as...
Why Vaccines Still Matter: Valneva CEO Thomas Lingelbach on Science, Politics, and the Future of Vaccine Innovation
Few areas of healthcare have saved more lives, or generated more debate, than vaccines. For...
From Make-or-Break to Record-Breaking: How One Phase 3 Readout Delivered the Biggest Biotech Stock Surge in NASDAQ History
In biotech, Phase 3 data can change everything, or end everything. Few stories capture that...
Free Database of the Top 100 Public Biotechs in Europe
The FlotBio Map is live at map.flot.bio 🙌 Here’s a bit of background FlotBio Map...
Never Miss a New Episode 💌
Trusted by 2500+ biopharma professionals from top companies like argenx, Roche, and Forbion. No spam, no noise.
Watch & Subscribe
